GHRP-6 Side Effects: A Ghrelin-Mimetic Without FDA Approval
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue that activates the ghrelin (GHS-R) receptor. It is not approved by the FDA, EMA, or TGA for any therapeutic indication. Marketed off-label for body composition, those uses are not characterised by regulator review.
GHRP-6 is not FDA-approved and lacks controlled human safety data. Not FDA- or TGA-approved. Off-label use only. WADA prohibits competitive use. This page summarises the published literature and regulator positions. It is not medical advice.
Key Takeaways
- GHRP-6 is a ghrelin-mimetic GH secretagogue.
- Not FDA-, EMA-, or TGA-approved.
- Notable appetite-stimulating effect, alongside cortisol and prolactin elevation.
- WADA prohibits use in competitive sport.
- Compounded or gray-market product is not pharmaceutical-grade.
What is GHRP-6, and what is it marketed for?
Growth hormone-releasing peptide 6. GHRP-6 activates the GHS-R1a receptor (the ghrelin receptor) and stimulates pulsatile GH release. Among the early ghrelin mimetics, GHRP-6 produces a particularly strong appetite-stimulating effect.
What side effects and safety concerns have been reported?
The summary below draws from the published literature and regulator statements. Severity classification follows the source documents.
| Concern | What has been reported | Source |
|---|---|---|
| Marked appetite increase | Stronger appetite effect than newer secretagogues | Direct ghrelin-receptor agonism |
| Cortisol and prolactin | Modest increases reported in trials | Common to GH-secretagogues |
| Fluid retention, joint discomfort | Common to GH-axis stimulation | Reported across GH-secretagogue trials |
| WADA prohibited | Listed under WADA prohibited substances (S2) | Use in competitive sport is prohibited |
| Long-term safety | Not characterised in long-term human use | Limited published long-term data |
Taking GHRP-6 alongside prescription medicines?
Allmeds scans interactions across your full medication list. Free for individuals.
Common Questions About GHRP-6
No. GHRP-6 is not approved by the FDA, EMA, or TGA for any therapeutic use.
GHRP-6 activates the ghrelin receptor, and ghrelin is the primary appetite-stimulating hormone. This is a direct mechanistic effect and a common reason published reviews describe a stronger appetite signal than with newer secretagogues like ipamorelin.
Yes. WADA prohibits GHRP-6.
Long-term safety of GHRP-6 is not characterised in regulator-reviewed datasets. Compounded GHRP-6 is not pharmaceutical-grade.
References
- Bowers CY. GH releasing peptides: structure and kinetics. J Pediatr Endocrinol Metab. 1993. Source.
- Smith RG et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997. Source.
- World Anti-Doping Agency. WADA Prohibited List. Source.
- U.S. Food & Drug Administration. FDA position on bulk drug substances for compounding. Source.